HMGB1 Mediates Anemia of Inflammation in Murine Sepsis Survivors

Patients surviving sepsis develop anemia, but the molecular mechanism is unknown. Here we observed that mice surviving polymicrobial gram-negative sepsis develop hypochromic, microcytic anemia with reticulocytosis. The bone marrow of sepsis survivors accumulates polychromatophilic and orthochromatic erythroblasts. Compensatory extramedullary erythropoiesis in the spleen is defective during terminal differentiation. Circulating tumor necrosis factor (TNF) and interleukin (IL)-6 are elevated for 5 d after the onset of sepsis, and serum high-mobility group box 1 (HMGB1) levels are increased from d 7 until at least d 28. Administration of recombinant HMGB1 to healthy mice mediates anemia with extramedullary erythropoiesis and significantly elevated reticulocyte counts. Moreover, administration of anti-HMGB1 monoclonal antibodies after sepsis significantly ameliorates the development of anemia (hematocrit 48.5 ± 9.0% versus 37.4 ± 6.1%, p < 0.01; hemoglobin 14.0 ± 1.7 versus 11.7 ± 1.2 g/dL, p < 0.01). Together, these results indicate that HMGB1 mediates anemia by interfering with erythropoiesis, suggesting a potential therapeutic strategy for anemia in sepsis.

[1]  Huan Yang,et al.  High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule , 2015, Molecular medicine.

[2]  K. Tracey,et al.  MD-2 is required for disulfide HMGB1–dependent TLR4 signaling , 2015, The Journal of experimental medicine.

[3]  T. Ganz,et al.  Anemia of inflammation. , 2014, Hematology/oncology clinics of North America.

[4]  M. Levy,et al.  Inflammatory Response in Islet Transplantation , 2014, International journal of endocrinology.

[5]  C. Deutschman,et al.  Sepsis: current dogma and new perspectives. , 2014, Immunity.

[6]  S. Rivella,et al.  Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus. , 2014, Blood.

[7]  Jun Zhou,et al.  Endogenous HMGB1 is required in endotoxin tolerance. , 2013, The Journal of surgical research.

[8]  V. Pavlov,et al.  HMGB1 mediates splenomegaly and expansion of splenic CD11b+ Ly-6Chigh inflammatory monocytes in murine sepsis survivors , 2013, Journal of internal medicine.

[9]  K. Tracey,et al.  The many faces of HMGB1: molecular structure‐functional activity in inflammation, apoptosis, and chemotaxis , 2013, Journal of leukocyte biology.

[10]  L. De Franceschi,et al.  Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis. , 2013, Blood.

[11]  B. Volpe,et al.  HMGB1 Mediates Cognitive Impairment in Sepsis Survivors , 2012, Molecular medicine.

[12]  T. Lagu,et al.  Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007 , 2012, Critical care medicine.

[13]  R. Star,et al.  Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1. , 2011, Kidney international.

[14]  U. Andersson,et al.  Monoclonal Anti-HMGB1 (High Mobility Group Box Chromosomal Protein 1) Antibody Protection in Two Experimental Arthritis Models , 2011, Molecular medicine.

[15]  R. Paulson,et al.  Stress erythropoiesis: new signals and new stress progenitor cells , 2011, Current opinion in hematology.

[16]  S. Chadban,et al.  HMGB1 contributes to kidney ischemia reperfusion injury. , 2010, Journal of the American Society of Nephrology : JASN.

[17]  S. Bandinelli,et al.  Proinflammatory state, hepcidin, and anemia in older persons. , 2010, Blood.

[18]  S. Chadban,et al.  HMGB 1 Contributes to Kidney Ischemia Reperfusion Injury , 2010 .

[19]  S. Heck,et al.  Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis , 2009, Proceedings of the National Academy of Sciences.

[20]  John A Kellum,et al.  Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. , 2007, Archives of internal medicine.

[21]  D. Angus,et al.  Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis* , 2007, Critical care medicine.

[22]  K. Tracey,et al.  Role of HMGB1 in apoptosis-mediated sepsis lethality , 2006, The Journal of Experimental Medicine.

[23]  G. Clermont,et al.  Predicting late anemia in critical illness , 2006, Critical care.

[24]  L. Goodnough,et al.  Anemia of chronic disease. , 2005, The New England journal of medicine.

[25]  K. Tracey,et al.  Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock* , 2005, Critical care medicine.

[26]  K. Tracey,et al.  Recombinant HMGB1 with cytokine-stimulating activity. , 2004, Journal of immunological methods.

[27]  Elizabeta Nemeth,et al.  IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. , 2004, The Journal of clinical investigation.

[28]  K. Tracey,et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Elizabeta Nemeth,et al.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. , 2003, Blood.

[30]  J. Vincent,et al.  Anemia and blood transfusion in critically ill patients. , 2002, JAMA.

[31]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[32]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[33]  D. Fuchs,et al.  Erythropoietin response is blunted in critically ill patients. , 1997, Intensive care medicine.

[34]  L. Moldawer,et al.  Cachectin/tumor necrosis factor‐α alters red blood cell kinetics and induces anemia in vivo , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  K. Tracey,et al.  Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation , 1988, The Journal of experimental medicine.